Gilabert J, Estellés A, Cano A, España F, Barrachina R, Grancha S, Aznar J, Tortajada M
Department of Obstetrics and Gynecology, La Fe University Hospital, Valencia, Spain.
Am J Obstet Gynecol. 1995 Dec;173(6):1849-54. doi: 10.1016/0002-9378(95)90439-5.
The aim of this study was to analyze several fibrinolytic components and coagulation inhibitors in postmenopausal women and had to evaluate the effect of hormone replacement therapy.
Several hemostatic parameters were evaluated in 75 postmenopausal women before and after 3 to 4 and 12 months of hormone therapy.
An increase in plasma fibrinolytic activity primarily related to a significant increase in tissue-type plasminogen activator and a decrease in plasminogen activator inhibitor type 1 was observed in women receiving hormone replacement therapy. A significant decrease in protein S and lipoprotein(a) was detected under therapy. No modifications in tissue-type plasminogen activator/plasminogen activator inhibitor-1 and activated protein C/alpha 1-antitrypsin complexes, urokinase activity, plasminogen, and antithrombin III were detected.
The increase in fibrinolytic activity and the decrease in lipoprotein(a) levels observed in women receiving hormone replacement therapy could help decrease the risk of coronary disease associated with the postmenopausal state.
本研究旨在分析绝经后女性的几种纤溶成分和凝血抑制剂，并评估激素替代疗法的效果。
在75名绝经后女性接受激素治疗前以及治疗3至4个月和12个月后，对多项止血参数进行了评估。
接受激素替代疗法的女性血浆纤溶活性增加，主要与组织型纤溶酶原激活物显著增加及纤溶酶原激活物抑制剂1型减少有关。治疗期间检测到蛋白S和脂蛋白(a)显著降低。未检测到组织型纤溶酶原激活物/纤溶酶原激活物抑制剂-1和活化蛋白C/α1-抗胰蛋白酶复合物、尿激酶活性、纤溶酶原及抗凝血酶III的变化。
接受激素替代疗法的女性纤溶活性增加及脂蛋白(a)水平降低，可能有助于降低绝经后状态相关的冠心病风险。
